Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells

被引:61
作者
Junk, Damian J. [1 ]
Vrba, Lukas [1 ]
Watts, George S. [1 ]
Oshiro, Marc M. [1 ]
Martinez, Jesse D. [1 ]
Futscher, Bernard W. [1 ]
机构
[1] Arizona Canc Ctr, Tucson, AZ 85724 USA
来源
NEOPLASIA | 2008年 / 10卷 / 05期
基金
美国国家卫生研究院; 美国国家科学基金会;
关键词
D O I
10.1593/neo.08120
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aberrations of p53 occur in most, if not all, human cancers. In breast cancer, p53 mutation is the most common genetic defect related to a single gene. Immortalized human mammary epithelial cells resemble the earliest forms of aberrant breast tissue growth but do not express many malignancy-associated phenotypes. We created a model of human mammary epithelial tumorigenesis by infecting hTERT-HME1 immortalized human mammary epithelial cells expressing wild-type p53 with four different mutant p53 constructs to determine the role of p53 mutation on the evolution of tumor phenotypes. We demonstrate that different mutant/wild-type p53 heterozygous models generate loss of function, dominant negative activity, and a spectrum of gain of function activities that induce varying degrees of invasive potential. We suggest that this model can be used to elucidate changes that occur in early stages of human mammary epithelial tumorigenesis. These changes may constitute novel biomarkers or reveal novel treatment modalities that could inhibit progression from primary to metastatic breast disease.
引用
收藏
页码:450 / 461
页数:12
相关论文
共 42 条
[21]   Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression [J].
Oshiro, MM ;
Watts, GS ;
Wozniak, RJ ;
Junk, DJ ;
Munoz-Rodriguez, JL ;
Domann, FE ;
Futscher, BW .
ONCOGENE, 2003, 22 (23) :3624-3634
[22]   Cytogenetic characterization and H-ras associated transformation of immortalized human mammary epithelial cells [J].
Rao, Krishna ;
Alper, Oezge ;
Opheim, Kent E. ;
Bonnet, George ;
Wolfe, Kristine ;
Bryant, Eileen ;
Larivee, Siobhan O'Hara ;
Porter, Peggy ;
McDougall, James K. .
CANCER CELL INTERNATIONAL, 2006, 6 (1)
[23]   MUTATIONS IN P53 AS POTENTIAL MOLECULAR MARKERS FOR HUMAN BREAST-CANCER [J].
RUNNEBAUM, IB ;
NAGARAJAN, M ;
BOWMAN, M ;
SOTO, D ;
SUKUMAR, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (23) :10657-10661
[24]   Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1 [J].
Sampath, J ;
Sun, DX ;
Kidd, VJ ;
Grenet, J ;
Gandhi, A ;
Shapiro, LH ;
Wang, QJ ;
Zambetti, GP ;
Schuetz, JD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (42) :39359-39367
[25]   Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma [J].
Sato, N ;
Parker, AR ;
Fukushima, N ;
Miyagi, Y ;
Iacobuzio-Donahue, C ;
Eshleman, JR ;
Goggins, M .
ONCOGENE, 2005, 24 (05) :850-858
[26]   Modulation of gene expression by tumor-derived p53 mutants [J].
Scian, MJ ;
Stagliano, KER ;
Ellis, MA ;
Hassan, S ;
Bowman, M ;
Miles, MF ;
Deb, SP ;
Deb, S .
CANCER RESEARCH, 2004, 64 (20) :7447-7454
[27]  
SHAULSKY G, 1991, CANCER RES, V51, P5232
[28]  
SINGH S, 1993, HUM GENET, V90, P635
[29]   The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry [J].
Sjogren, S ;
Inganas, M ;
Norberg, T ;
Lindgren, A ;
Nordgren, H ;
Holmberg, L ;
Bergh, J .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (3-4) :173-182
[30]  
Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23